HC Wainwright Raises Earnings Estimates for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings estimates for shares of Pyxis Oncology in a report released on Tuesday, March 24th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.35) per share for the quarter, up from their prior estimate of ($0.39). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.85) EPS, FY2028 earnings at ($0.34) EPS and FY2030 earnings at $0.83 EPS.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter, compared to the consensus estimate of $0.13 million.

Several other equities analysts have also issued reports on PYXS. Stifel Nicolaus lowered their target price on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday. Royal Bank Of Canada cut their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $1.39 on Thursday. The stock has a market cap of $87.33 million, a PE ratio of -1.08 and a beta of 1.45. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The firm’s 50-day simple moving average is $1.50 and its two-hundred day simple moving average is $2.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PYXS. Maia Wealth LLC bought a new stake in shares of Pyxis Oncology during the fourth quarter valued at approximately $25,000. Fox Run Management L.L.C. purchased a new position in Pyxis Oncology in the 4th quarter worth approximately $26,000. Engineers Gate Manager LP bought a new position in Pyxis Oncology in the 4th quarter valued at approximately $26,000. Avanza Fonder AB bought a new position in Pyxis Oncology in the 4th quarter valued at approximately $31,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Pyxis Oncology during the 3rd quarter valued at $77,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted several EPS estimates (FY2026→-0.95 from -1.28; FY2027→-0.85; FY2028→-0.34; FY2029→0.27; FY2030→0.83) while keeping a $7 price target — a clear bullish signal for future earnings trajectory. Read More.
• Positive Sentiment: Recent quarter: Pyxis reported a beat on the March quarter EPS (-$0.29 vs. -$0.35 consensus) and $11.0M revenue, which supports the analyst upgrades and contributed to improved sentiment. Read More.
• Neutral Sentiment: Analyst coverage remains mixed overall — consensus is still a “Moderate Buy” with an average $7.00 target, but ratings and targets vary across shops (five Buys, one Hold, one Sell), so conviction is not uniform. Read More.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed multiple sales (most recently 13,896 shares at about $1.03). Insider exits can weigh on sentiment even if done for liquidity reasons; SEC Form 4 is filed. Read More. — SEC filing: Read More.
• Negative Sentiment: Some shops trimmed upside: Stifel reduced its price target (reported recently) which could temper momentum from HC Wainwright’s bullish note. Read More.
• Negative Sentiment: Within HC Wainwright’s note there was a small near‑term downgrade to Q2 2026 EPS (to -$0.36 from -$0.32), a mixed signal for the next quarter despite longer‑term upside revisions. Read More.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.